MoonLake Immunotherapeutics
NASDAQ:MLTXBiotechnology
+$0.13 today
- Market cap
- $918.30M
- Beta
- 1.04
- P/E (TTM)
- -5.4
- EPS (TTM)
- -$3.61
Volume 1.32M
Average 0.99M
MLTX Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
MoonLake ImmunotherapeuticsNASDAQ: MLTX
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables rises 92.9% from a year ago
Net receivables stood at $5.76M at the end of Q1 FY2026, up 92.9% from a year earlier and up 18.4% from the prior quarter. Over 3 fiscal years it compounded at +182.0% a year.
Context
- Net receivables amounted to 1.4% of total assets at the end of Q1 FY2026, up 0.9 pp from a year earlier.
- Net receivables increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps rising in the next quarterly balance sheet after a +92.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 4.87M USD
- Year-over-year change
- +71.3%
- 4-year CAGR
- +139.2%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.87M | +71.3% |
| FY2024 | 2024-12-31 | 2.84M | +169.0% |
| FY2023 | 2023-12-31 | 1.06M | +386.7% |
| FY2022 | 2022-12-31 | 217.13K | +45.9% |
| FY2021 | 2021-12-31 | 148.77K | — |
Net Receivables vs competitors
How MLTX compares with its peers on the latest reported figures
- MLTX's Mar 2026 net receivables of $5.76M is the 3rd highest of the 11 companies compared; the peer median is $133.5K.
- Its year-over-year change of +92.9% is the 3rd highest of 7, against a peer median of -3.5%.
- Net receivables amounts to 1.4% of total assets for MLTX, versus a peer median of 0.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $25.75M | +44.0% | +187.9% | 7.8% | |
| Aug 2026 | $20M | — | — | 1.7% | |
| Mar 2026 | $5.76M | +92.9% | +182.0% | 1.4% | |
| Mar 2026 | $4.81M | +1825.6% | +125.7% | 2.4% | |
ALMSAlumis Inc. Common Stock | Jun 2026 | $3.86M | -50.9% | +60.9% | 0.7% |
| Dec 2025 | $161K | -84.7% | -11.5% | 0.3% | |
| Jun 2026 | $106K | +171.8% | -73.7% | 0.0% | |
ORKAOruka Therapeutics, Inc. | Sep 2026 | $0 | — | — | 0.0% |
| Jun 2026 | $0 | — | — | 0.0% | |
ZURAZura Bio Limited | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | -100.0% | -70.3% | 0.0% | |
| Peer median (excluding MLTX) | $133.5K | -3.5% | +24.7% | 0.1% | |
Competitors are the stored peer set for MLTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 8.04M | 39.51M | 451.17M | 180.43M | 334.52M |
| Short-term Investments | 0 | 32.61M | 59.84M | 267.6M | 59.45M |
| Net Receivables | 148.77K | 217.13K | 1.06M | 2.84M | 4.87M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 9.64M | 76.51M | 514.17M | 474.29M | 421.69M |
| Property, Plant & Equipment (Net) | 45.74K | 331.97K | 3.95M | 3.64M | 2.14M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 115.04M | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | (115.04M) | (0) | 8.42M | 0 | 596K |
| Total Non-current Assets | 45.74K | 331.97K | 12.37M | 3.64M | 2.74M |
| Total Assets | 9.68M | 76.84M | 526.54M | 477.93M | 424.43M |
| Account Payables | 1.23M | 47.48K | 1.46M | 8.68M | 0 |
| Short-term Debt | 15M | 0 | 0 | 0 | 1.23M |
| Tax Payables | 63.92K | 109.83K | 367.98K | 642.11K | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.3M | 109.83K | 2.78M | 4.24M | 40.83M |
| Total Current Liabilities | 21.09M | 7.67M | 9.97M | 22.46M | 45.48M |
| Long-term Debt | 0 | 0 | 0 | 0 | 74.47M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 239.86K | 282.21K | 583.43K | 620.68K | (374K) |
| Total Non-current Liabilities | 239.86K | 411.16K | 3.08M | 2.08M | 74.47M |
| Total Liabilities | 21.33M | 8.08M | 13.05M | 24.54M | 119.95M |
| Common Stock | 38.54K | 5.27K | 6.3K | 6.39K | 7K |
| Retained Earnings | (53.64M) | (80.65M) | (116.66M) | (235.59M) | (462.91M) |
| Accumulated OCI | (168.18K) | 350.95K | 2.36M | 5M | 604K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 19.87M | 17.82M | 6.57M | 0 |
| Total Equity | (11.65M) | 68.77M | 513.49M | 453.39M | 304.48M |
| Total Debt | 15M | 282.58K | 3.7M | 2.83M | 75.71M |
| Net Debt | 6.96M | (39.22M) | (447.47M) | (177.6M) | (258.81M) |
MoonLake Immunotherapeutics
NASDAQ:MLTX
Intrinsic Alpha fair value
Locked
Current Price
$10.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.